Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.
hepatocellular carcinoma
liver cancer
racial disparity
therapeutic outcomes
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
17
03
2023
received:
31
12
2022
accepted:
10
04
2023
medline:
22
8
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The incidence of HCC is affected by genetic and non-genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT-rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6-phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E-cadherin, have been shown to contribute to the occurrence of HCC. Non-genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non-alcoholic fatty liver disease (NAFLD), increase the risk of HCC. The severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non-minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non-Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC. Assessment and treatment of HCC must be consistent using evidence-based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.
Sections du résumé
BACKGROUND
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The incidence of HCC is affected by genetic and non-genetic factors. Genetically, mutations in the genes, tumor protein P53 (TP53), catenin beta 1 (CTNNB1), AT-rich interaction domain 1A (ARIC1A), cyclin dependent kinase inhibitor 2A (CDKN2A), mannose 6-phosphate (M6P), smooth muscle action against decapentaplegic (SMAD2), retinoblastoma gene (RB1), cyclin D, antigen presenting cells (APC), AXIN1, and E-cadherin, have been shown to contribute to the occurrence of HCC. Non-genetic factors, including alcohol consumption, exposure to aflatoxin, age, gender, presence of hepatitis B (HBV), hepatitis C (HCV), and non-alcoholic fatty liver disease (NAFLD), increase the risk of HCC.
RECENT FINDINGS
The severity of the disease and its occurrence vary based on geographical location. Furthermore, men and minorities have been shown to be disproportionately affected by HCC, compared with women and non-minorities. Ethnicity has been reported to significantly affect tumorigenesis and clinical outcomes in patients diagnosed with HCC. Generally, differences in gene expression and/or the presence of comorbid medical diseases affect or influence the progression of HCC. Non-Caucasian HCC patients are significantly more likely to have poorer survival outcomes, compared to their Caucasian counterparts. Finally, there are a number of factors that contribute to the success rate of treatments for HCC.
CONCLUSION
Assessment and treatment of HCC must be consistent using evidence-based guidelines and standardized outcomes, as well as international clinical practice guidelines for global consensus. Standardizing the assessment approach and method will enable comparison and improvement of liver cancer research through collaboration between researchers, healthcare providers, and advocacy groups. In this review, we will focus on discussing epidemiological factors that result in deviations and changes in treatment approaches for HCC.
Identifiants
pubmed: 37344125
doi: 10.1002/cnr2.1821
pmc: PMC10440848
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1821Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Lancet. 1989 Oct 28;2(8670):1006-8
pubmed: 2572740
Medicine (Baltimore). 2018 Aug;97(33):e11872
pubmed: 30113483
Clin Mol Hepatol. 2021 Jan;27(1):157-174
pubmed: 33238333
Clin Transl Med. 2019 May 6;8(1):13
pubmed: 31056726
Liver Int. 2016 Oct;36(10):1507-15
pubmed: 27009849
J Hepatol. 2019 Feb;70(2):284-293
pubmed: 30658729
Aging (Albany NY). 2021 Oct 11;13(19):23416-23434
pubmed: 34633987
Immunol Rev. 2019 Nov;292(1):149-163
pubmed: 31883174
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
QJM. 2012 Feb;105(2):109-13
pubmed: 22252919
Adv Exp Med Biol. 2017;1018:11-21
pubmed: 29052129
Hepatology. 2020 Aug;72(2):535-547
pubmed: 31808181
Gastroenterology. 2015 Jun;148(7):1294-310
pubmed: 25747274
Liver Cancer. 2020 Sep;9(5):563-582
pubmed: 33083281
Front Endocrinol (Lausanne). 2021 Dec 23;12:808526
pubmed: 35002979
Clin Liver Dis. 2016 Aug;20(3):445-56
pubmed: 27373608
J Gastrointest Cancer. 2017 Sep;48(3):238-240
pubmed: 28626852
Oncogene. 2007 Apr 2;26(15):2166-76
pubmed: 17401425
Am J Clin Oncol. 2018 Sep;41(9):874-881
pubmed: 28537989
Hepatology. 2012 Aug;56(2):422-33
pubmed: 22105832
Clin Microbiol Infect. 2016 Oct;22(10):853-861
pubmed: 27476823
Int J Mol Sci. 2022 Jan 02;23(1):
pubmed: 35008926
World J Gastroenterol. 2008 Jul 21;14(27):4300-8
pubmed: 18666317
World J Gastroenterol. 2010 Aug 7;16(29):3603-15
pubmed: 20677332
J Viral Hepat. 2009 Feb;16(2):94-103
pubmed: 19175878
Aliment Pharmacol Ther. 2017 Nov;46(9):856-863
pubmed: 28857208
PLoS One. 2021 Feb 4;16(2):e0246143
pubmed: 33539397
Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:5320-5325
pubmed: 33019185
J Natl Compr Canc Netw. 2021 May 28;19(9):1063-1071
pubmed: 34077908
World J Gastroenterol. 2013 Dec 21;19(47):8808-21
pubmed: 24379604
Int J Mol Sci. 2016 May 20;17(5):
pubmed: 27213358
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Int J Environ Res Public Health. 2020 Apr 29;17(9):
pubmed: 32365650
Drug Saf. 2021 Nov;44(11):1125-1149
pubmed: 34533782
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1:e1821
pubmed: 37344125
World J Gastroenterol. 2018 Jan 7;24(1):1-4
pubmed: 29358876
Lancet. 2002 Dec 14;360(9349):1921-6
pubmed: 12493258
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1193-1199
pubmed: 33737301
Hepatology. 2007 Jan;45(1):42-52
pubmed: 17187432
Cancers (Basel). 2018 Feb 09;10(2):
pubmed: 29425151
Clin Liver Dis. 2015 May;19(2):223-38
pubmed: 25921660
World J Hepatol. 2013 Oct 27;5(10):528-40
pubmed: 24179612
Carcinogenesis. 2013 Aug;34(8):1800-5
pubmed: 23322152
N Engl J Med. 2015 Aug 20;373(8):705-13
pubmed: 26196665
Biomedicines. 2022 Jun 02;10(6):
pubmed: 35740326
J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211-21
pubmed: 12354839
World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):477-489
pubmed: 27867681
J Clin Oncol. 2005 Jul 20;23(21):4742-54
pubmed: 16034050
J Hum Genet. 2021 Sep;66(9):845-851
pubmed: 33958712
J Gastroenterol Hepatol. 2020 Dec;35(12):2210-2219
pubmed: 32343449
Hepatol Res. 2012 Jan;42(1):1-14
pubmed: 21917086
J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S377-84
pubmed: 12472967
Clin Liver Dis (Hoboken). 2021 Jun 04;17(5):353-358
pubmed: 34136141
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
Nat Rev Gastroenterol Hepatol. 2022 Mar;19(3):147
pubmed: 35115721
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hepatol Commun. 2022 May;6(5):1186-1197
pubmed: 34796703
Liver Int. 2022 Aug;42(9):2029-2041
pubmed: 35319165
Hepatology. 2018 May;67(5):1726-1736
pubmed: 28941364
Eur J Cancer. 2012 Sep;48(14):2125-36
pubmed: 22405700
Cancer. 2017 Apr 1;123(7):1202-1211
pubmed: 28117886
Aliment Pharmacol Ther. 2017 Jan;45(1):169-177
pubmed: 27862091
Hepatology. 2010 Jun;51(6):1972-8
pubmed: 20209604
Front Med (Lausanne). 2022 Jun 24;9:899420
pubmed: 35814750
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96
pubmed: 15508108
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
Clin Microbiol Infect. 2009 Nov;15(11):964-70
pubmed: 19874379
Cancers (Basel). 2021 Aug 23;13(16):
pubmed: 34439391
BMJ Open. 2020 Aug 3;10(8):e036663
pubmed: 32747349
J Clin Invest. 2007 Sep;117(9):2713-22
pubmed: 17717605
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4770-4780
pubmed: 32071245
Br J Cancer. 2005 Feb 14;92(3):607-12
pubmed: 15685242
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Nature. 2011 Jul 06;475(7354):106-9
pubmed: 21734707
Arch Intern Med. 2007 Oct 8;167(18):1983-9
pubmed: 17923599
Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):37-49
pubmed: 36258033
Int J Cancer. 2021 Dec 15;149(12):2020-2031
pubmed: 34460109
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):180-3
pubmed: 26629287
Cancer. 2004 Sep 1;101(5):1009-17
pubmed: 15329910
Cancer Res. 2007 Mar 15;67(6):2497-507
pubmed: 17363567
Biomed Pharmacother. 2020 Dec;132:110851
pubmed: 33080466
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
World J Gastroenterol. 2014 Sep 7;20(33):11630-40
pubmed: 25206269
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Lancet. 2000 Mar 11;355(9207):887-91
pubmed: 10752705
Liver Int. 2016 Mar;36(3):317-24
pubmed: 26601627
Oncol Lett. 2013 Apr;5(4):1087-1092
pubmed: 23599745
Lancet Gastroenterol Hepatol. 2017 Feb;2(2):103-111
pubmed: 28403980
J Clin Invest. 2022 Feb 15;132(4):
pubmed: 35166233
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):17
pubmed: 29296152
Int J Organ Transplant Med. 2014;5(3):87-96
pubmed: 25184029
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Public Health Rep. 2014 Jan-Feb;129 Suppl 2:19-31
pubmed: 24385661
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):279-288
pubmed: 28603096
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
CA Cancer J Clin. 2017 Jul 8;67(4):273-289
pubmed: 28586094
Clin Gastroenterol Hepatol. 2020 Jan;18(1):242-248.e5
pubmed: 31042582
Hepatology. 2021 Aug;74(2):741-759
pubmed: 33529367
World J Gastroenterol. 2014 Nov 21;20(43):15943-54
pubmed: 25473148
J Hepatol. 2019 Aug;71(2):313-322
pubmed: 31071367
Am J Gastroenterol. 2015 Nov;110(11):1629-31
pubmed: 26618430
Ann Intern Med. 2014 Mar 4;160(5):293-300
pubmed: 24737271
J Hepatol. 2020 May;72(5):990-1002
pubmed: 32044402
J Hepatol. 2022 Dec;77(6):1598-1606
pubmed: 36208844
Hepatol Commun. 2022 Jul;6(7):1813-1826
pubmed: 35234371
JHEP Rep. 2019 Jun 17;1(3):162-169
pubmed: 32039366
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):156-164
pubmed: 28404072
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Br J Cancer. 2018 Apr;118(7):1005-1012
pubmed: 29520041
Cancers (Basel). 2021 Jul 23;13(15):
pubmed: 34359611
Int J Cancer. 2018 Jun 15;142(12):2471-2477
pubmed: 29388206
Ann Oncol. 2014 Aug;25(8):1526-35
pubmed: 24631946
Case Rep Endocrinol. 2018 Feb 15;2018:8046378
pubmed: 29662707
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2
pubmed: 23041539
World J Hepatol. 2018 Nov 27;10(11):849-855
pubmed: 30533185
Gut. 2010 Oct;59(10):1303-7
pubmed: 20650925
World J Hepatol. 2015 Jun 8;7(10):1377-89
pubmed: 26052383
Eur J Cancer. 2021 Oct 16;158:133-143
pubmed: 34666215
Anal Cell Pathol (Amst). 2020 Feb 3;2020:8157406
pubmed: 32089989
J Hepatol. 2011 Dec;55(6):1215-21
pubmed: 21703206
Hepatology. 2020 Nov;72(5):1654-1665
pubmed: 32017165
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48
pubmed: 30670200
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Cold Spring Harb Perspect Med. 2014 Oct 30;4(12):a024935
pubmed: 25359547
Curr Hepatol Rep. 2020 Dec;19(4):462-469
pubmed: 33828937
Cold Spring Harb Perspect Med. 2017 Apr 3;7(4):
pubmed: 28096241
Genome Res. 2013 Sep;23(9):1422-33
pubmed: 23788652
Hepatology. 2010 Dec;52(6):2034-43
pubmed: 21105107
J Food Prot. 1995 Dec;58(12):1395-1404
pubmed: 31159052
Arch Intern Med. 1990 May;150(5):1051-4
pubmed: 2158773
Oncologist. 2007 Nov;12(11):1321-31
pubmed: 18055852
Biomed Res Int. 2017;2017:1609575
pubmed: 28401148
Gastroenterology. 2016 Sep;151(3):472-480.e1
pubmed: 27269245
Clin Infect Dis. 2018 Sep 14;67(7):1010-1017
pubmed: 29566246
Dig Dis Sci. 2019 Apr;64(4):910-917
pubmed: 30835028
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Hepatol. 2019 Sep;71(3):523-533
pubmed: 31145929
Hum Mol Genet. 2014 Aug 1;23(15):4077-85
pubmed: 24670599
J Hepatol. 2014 Jan;60(1):110-7
pubmed: 23978719
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13568-73
pubmed: 18757741
Milbank Q. 2009 Jun;87(2):443-94
pubmed: 19523125
Gastroenterology. 2005 Jul;129(1):113-21
pubmed: 16012941
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
Curr Opin Genet Dev. 2017 Feb;42:56-67
pubmed: 28391084
J Neurochem. 2011 Nov;119(3):447-59
pubmed: 21838783
Annu Rev Immunol. 2008;26:535-84
pubmed: 18303999
JCO Glob Oncol. 2021 May;7:756-766
pubmed: 34043413
Cancer Lett. 2014 Apr 10;345(2):210-5
pubmed: 23871966
Int J Cancer. 1998 Jan 30;75(3):347-54
pubmed: 9455792
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Liver Int. 2015 Oct;35(10):2203-17
pubmed: 26123841
N Engl J Med. 2017 Nov 23;377(21):2063-2072
pubmed: 29166236
J Int AIDS Soc. 2011 Nov 11;14:53
pubmed: 22078415
Int J Mol Sci. 2020 Oct 18;21(20):
pubmed: 33080952
N Engl J Med. 2016 Jun 16;374(24):2324-34
pubmed: 27305192
Clin Liver Dis (Hoboken). 2015 Jan 20;4(6):143-145
pubmed: 30992943
Gastroenterology Res. 2017 Oct;10(5):271-279
pubmed: 29118867
PLoS One. 2015 Oct 29;10(10):e0140908
pubmed: 26512983
J Gen Virol. 2002 Aug;83(Pt 8):2059-2073
pubmed: 12124470
Liver Int. 2018 Jan;38(1):136-143
pubmed: 28640517
Inflamm Regen. 2016 Oct 18;36:19
pubmed: 29259692
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1679-1687
pubmed: 32693047
Front Microbiol. 2017 Jan 17;7:2170
pubmed: 28144235
World J Gastroenterol. 2014 Sep 28;20(36):12945-55
pubmed: 25278690
Glob Health Action. 2009 Sep 28;2:
pubmed: 20027253
Arch Surg. 2010 Dec;145(12):1158-63
pubmed: 21173289
Ann Surg. 2005 Jul;242(1):36-42
pubmed: 15973099
Viruses. 2010 Sep;2(9):2108-2133
pubmed: 21994721
Hepatology. 2005 Dec;42(6):1339-48
pubmed: 16317688
Nature. 1991 Apr 4;350(6317):427-8
pubmed: 1849234
Semin Liver Dis. 2000;20(1):17-35
pubmed: 10895429
World J Gastroenterol. 2010 Mar 28;16(12):1436-41
pubmed: 20333782
Nat Commun. 2018 Apr 24;9(1):1643
pubmed: 29691395
AJR Am J Roentgenol. 2021 Oct;217(4):933-943
pubmed: 33245680
J Gen Virol. 2000 Jan;81(Pt 1):67-74
pubmed: 10640543
Molecules. 2022 Oct 25;27(21):
pubmed: 36364057
Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):537-546
pubmed: 29737218
Hepatology. 2006 Apr;43(4):682-9
pubmed: 16502396
Toxicol Rep. 2021 Feb 19;8:376-385
pubmed: 33680863
BMC Cancer. 2009 Jun 26;9:204
pubmed: 19558663
World J Hepatol. 2012 Dec 27;4(12):342-55
pubmed: 23355912
Front Oncol. 2020 Feb 28;10:171
pubmed: 32185125
Science. 2001 Aug 10;293(5532):1103-5
pubmed: 11498582
World J Hepatol. 2017 Jan 8;9(1):48-56
pubmed: 28105258
Cancers (Basel). 2022 Sep 15;14(18):
pubmed: 36139633
Liver Cancer. 2018 May;7(2):134-147
pubmed: 29888204
Yonsei Med J. 2013 Jul;54(4):883-7
pubmed: 23709421
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Chin J Cancer Res. 2018 Dec;30(6):571-579
pubmed: 30700925
Lancet HIV. 2015 Aug;2(8):e319-27
pubmed: 26423374
Ann Hepatol. 2022 Sep-Oct;27(5):100727
pubmed: 35700934
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
World J Gastroenterol. 2014 May 14;20(18):5320-30
pubmed: 24833862
J Hepatol. 2010 Feb;52(2):252-7
pubmed: 20022654
Trop Med Int Health. 2021 Mar;26(3):335-342
pubmed: 33244817
Virology. 1994 Feb;198(2):489-503
pubmed: 8291231
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):900-909
pubmed: 29132759
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Gastroenterol. 2010;45(1):86-94
pubmed: 19789837
HPB (Oxford). 2021 Jun;23(6):868-876
pubmed: 33487553
Ann Hepatol. 2009;8 Suppl 1:S18-24
pubmed: 19381120
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
JGH Open. 2020 Apr 15;4(3):351-359
pubmed: 32514436
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345
Int J Cancer. 2016 Jun 1;138(11):2549-61
pubmed: 26537995
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
Front Oncol. 2017 May 04;7:85
pubmed: 28523248
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):422-424
pubmed: 34015351
J Gastroenterol. 2020 Jan;55(1):113-122
pubmed: 31720835